OneSource Pharma Eyes Obesity Drug Growth, Expansion

  Published 11 months ago

OneSource Pharma anticipates strong growth from obesity drugs as semaglutide patents expire in 2026, driving new orders and expansion plans.

  • Added 15 obesity/diabetes drug orders in FY2025, with more in pipeline and 30% CAGR expected through FY2028.
  • Competes with Piramal, Divi's; invests $100M to expand drug, device facilities and global manufacturing footprint.
  • Demerged from Strides in January, aiming for U.S. and Europe manufacturing presence post-listing.

You might like these

Kashmir Tourism Plummets After Violent Attacks

India Eases Gold Loan Rules & Bank Ownership

Jio Financial Services Shares Surge 4% on Broker Approval

ABB India Marks 30 Years on NSE

Prosus Delays PayU IPO, Focuses on Growth

RBI sDQI: Data Quality Improves for SCBs in 2025

Sensex, Nifty Open Flat on Inflation Worry

News that matters the most ⚡